Virginia Tech
    • Log in
    View Item 
    •   VTechWorks Home
    • Fralin Life Sciences Institute
    • Scholarly Works, Fralin Life Sciences Institute
    • View Item
    •   VTechWorks Home
    • Fralin Life Sciences Institute
    • Scholarly Works, Fralin Life Sciences Institute
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Probiotic bacteria produce conjugated linoleic acid locally in the gut that targets macrophage PPAR gamma to suppress colitis

    Thumbnail
    View/Open
    journal_pone_0031238.pdf (1.134Mb)
    Downloads: 403
    Date
    2012-02-21
    Author
    Bassaganya-Riera, Josep
    Viladomiu, Monica
    Pedragosa, Mireia
    De Simone, Claudio
    Carbo, Adria
    Shaykhutdinov, Rustem
    Jobin, Christian
    Arthur, Janelle C.
    Corl, Benjamin A.
    Vogel, Hans
    Storr, Martin
    Hontecillas, Raquel
    Metadata
    Show full item record
    Abstract
    Background: Inflammatory bowel disease (IBD) therapies are modestly successful and associated with significant side effects. Thus, the investigation of novel approaches to prevent colitis is important. Probiotic bacteria can produce immunoregulatory metabolites in vitro such as conjugated linoleic acid (CLA), a polyunsaturated fatty acid with potent anti-inflammatory effects. This study aimed to investigate the cellular and molecular mechanisms underlying the anti-inflammatory efficacy of probiotic bacteria using a mouse model of colitis. Methodology/Principal Findings: The immune modulatory mechanisms of VSL#3 probiotic bacteria and CLA were investigated in a mouse model of DSS colitis. Colonic specimens were collected for histopathology, gene expression and flow cytometry analyses. Immune cell subsets in the mesenteric lymph nodes (MLN), spleen, blood and colonic lamina propria cells were phenotypically and functionally characterized. Fecal samples and colonic contents were collected to determine the effect of VSL#3 and CLA on gut microbial diversity and CLA production. CLA and VSL#3 treatment ameliorated colitis and decreased colonic bacterial diversity, a finding that correlated with decreased gut pathology. Colonic CLA concentrations were increased in response to probiotic bacterial treatment, but without systemic distribution in blood. VSL#3 and CLA decreased macrophage accumulation in the MLN of mice with DSS colitis. The loss of PPAR γ in myeloid cells abrogated the protective effect of probiotic bacteria and CLA in mice with DSS colitis. Conclusions/Significance: Probiotic bacteria modulate gut microbial diversity and favor local production of CLA in the colon that targets myeloid cell PPAR γ to suppress colitis.
    URI
    http://hdl.handle.net/10919/48990
    Collections
    • Scholarly Works, Fralin Life Sciences Institute [542]
    • Scholarly Works, School of Animal Sciences [468]

    If you believe that any material in VTechWorks should be removed, please see our policy and procedure for Requesting that Material be Amended or Removed. All takedown requests will be promptly acknowledged and investigated.

    Virginia Tech | University Libraries | Contact Us
     

     

    VTechWorks

    AboutPoliciesHelp

    Browse

    All of VTechWorksCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects

    My Account

    Log inRegister

    Statistics

    View Usage Statistics

    If you believe that any material in VTechWorks should be removed, please see our policy and procedure for Requesting that Material be Amended or Removed. All takedown requests will be promptly acknowledged and investigated.

    Virginia Tech | University Libraries | Contact Us